NeuroPace, Inc. $NPCE Shares Acquired by First Light Asset Management LLC

Posted by Francis Steltz on Sep 10th, 2026

First Light Asset Management LLC increased its position in NeuroPace, Inc. (NASDAQ:NPCE – Free Report) by 16.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,861,167 shares of the company’s stock after buying an additional 401,201 shares during the quarter. NeuroPace comprises about 2.8% of First Light Asset Management LLC’s investment portfolio, making the stock its 15th biggest position. First Light Asset Management LLC owned 0.08% of NeuroPace worth $45,464,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in NPCE. Legal & General Group Plc grew its position in NeuroPace by 86.0% during the second quarter. Legal & General Group Plc now owns 2,679 shares of the company’s stock valued at $30,000 after acquiring an additional 1,239 shares during the period. Quantbot Technologies LP acquired a new stake in NeuroPace during the second quarter worth about $35,000. Quarry LP raised its holdings in shares of NeuroPace by 94.9% in the 3rd quarter. Quarry LP now owns 3,845 shares of the company’s stock worth $40,000 after purchasing an additional 1,872 shares during the period. California State Teachers Retirement System lifted its stake in shares of NeuroPace by 311.7% in the 2nd quarter. California State Teachers Retirement System now owns 5,673 shares of the company’s stock valued at $90,000 after purchasing an additional 4,295 shares in the last quarter. Finally, New York State Common Retirement Fund lifted its stake in shares of NeuroPace by 755.6% in the 4th quarter. New York State Common Retirement Fund now owns 7,700 shares of the company’s stock valued at $119,000 after purchasing an additional 6,800 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

NeuroPace Trading Down 1.8%

Shares of NPCE opened at $14.50 on Thursday. The stock’s 50-day moving average is $15.02 and its two-hundred day moving average is $15.26. The stock has a market cap of $497.64 million, a PE ratio of -25.44 and a beta of 1.94. NeuroPace, Inc. has a 12 month low of $9.22 and a 12 month high of $19.60. The company has a debt-to-equity ratio of 4.97, a current ratio of 4.94 and a quick ratio of 3.91.

NeuroPace (NASDAQ:NPCE – Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. The business had revenue of $22.83 million during the quarter, compared to analyst estimates of $22.61 million. NeuroPace had a negative return on equity of 105.64% and a negative net margin of 19.34%. Equities analysts forecast that NeuroPace, Inc. will post -0.67 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on NPCE. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of NeuroPace in a report on Wednesday, July 29th. Weiss Ratings restated a “sell (d-)” rating on shares of NeuroPace in a report on Wednesday, June 24th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of NeuroPace in a research report on Monday, August 17th. Guggenheim reiterated a “neutral” rating on shares of NeuroPace in a research note on Wednesday, July 29th. Finally, Mizuho began coverage on shares of NeuroPace in a research report on Thursday, July 23rd. They issued an “outperform” rating and a $22.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $19.29.

Get Our Latest Research Report on NPCE

NeuroPace Profile

(Free Report)

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.